GlassScriptPhysician profile
Catherine Furlani
NPI 1770631483
$2,582.37
in general payments reported to CMS, 2019-2025
42 companies · $615 in 2025
The $615 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $308 · 2022: $305 · 2023: $501 · 2024: $854 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,970.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $563.72 | 2021-2024 | Opdivo, Opdualag |
| Novartis Pharmaceuticals Corporation | $186.34 | 2023-2025 | |
| Daiichi Sankyo INC. | $151.85 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Celgene Corporation | $120.42 | 2023-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $115.34 | 2023-2024 | Talvey, Erleada, Tecvayli |
| Merck Sharp & Dohme LLC | $106.67 | 2023-2025 | Keytruda, Lynparza |
| Adc Therapeutics America, INC. | $92.76 | 2022-2025 | |
| Abbvie INC. | $89.94 | 2024-2025 | |
| Incyte Corporation | $73.08 | 2022-2025 | Jakafi, Monjuvi |
| Sobi, INC | $71.19 | 2024 | |
| Gilead Sciences, INC. | $67.99 | 2024-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $66.41 | 2023-2024 | Ninlaro, Iclusig, Alunbrig |
| Lilly USA, LLC | $56.18 | 2024-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $55.09 | 2022-2024 | Jemperli, Zejula, Ojjaara |
| Astrazeneca Pharmaceuticals LP | $54.43 | 2023-2024 | Calquence, Enhertu |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Catherine Furlani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.